Swedish venture capital manager Eir Ventures has rounded up a total of $138 million for its life sciences fund Eir Ventures I AB. The fund — launched just last year — is the firm’s first dedicated…
Viatris (Mylan/Pfizer’s Upjohn) and India’s Biocon Biologics are reportedly pondering whether to further entwine their biosimilar businesses into a $10 billion standalone company, according to sources…
The new J&J has a fresh corporate face to show the public — several in fact. As the healthcare conglomerate follows a now familiar pharma path in separating itself into an innovation-focused R&D-based…
When conducting preclinical tests in drug development, researchers have for years used different kinds of animal models, from mice to nonhuman primates. But what if the need for such models became…
A struggling Aprea Therapeutics got a boost Thursday morning after the biotech reported that the FDA had lifted one of the clinical holds on its one and only drug in the clinic. Remaining tight-lipped…
Catalent has entered a partnership with a cell therapy company that focuses on neurodegenerative diseases, taking on a tech transfer to manufacture treatments for ALS and PMS. BrainStorm Cell…
After being in stealth for nearly 11 months, a new biotech has made itself known, complete with an influx of cash from some big-name investors. K36 Therapeutics, an oncology biotech out of Cambridge,…
The newest building at Fujifilm Irvine Scientific’s Netherlands campus is open for business. The company, amidst a massive amount of expansion that has placed it in the top-five companies by…
Moderna and Pfizer-BioNTech are now racing to develop Omicron-specific boosters, hoping to be ready if the new immune-evasive variant becomes dominant globally. But it wasn’t always clear that variant…
Taipei’s Bora Pharmaceuticals has linked up with Taishin Healthcare to invest about $108 million into CDMOs and CROs in response to a booming business environment for both industries. The two…
